New York

MYLAN NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the product's rapidly escalating price.

The list price of the drug will remain the same, but the company said it would increase the maximum copay assistance programme to US$300 from US$100 for patients who pay for the 2-pak in cash or who are covered by a commercial health insurer.